ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

NIH Director Calls For Lifting Federal Ban on Embryonic Stem Cell Research.

March 23, 2007

NIH Proposes Center for Cell Biology

February 19, 1993

Clinical Center’s Cancer Nursing Recruitment Improved

January 10, 1986

Three Bomb Threats At NIH In One Week result In Evacuations, Investigations

August 2, 1996

NCI To Fund About 4,100 Grants; Increase Planned In Average Costs; Paylines Stable

November 20, 1998

FASEB: Focus on Research Funding, Not PR

June 14, 2013